Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola Interventions: Biological: Ad26.ZEBOV; Biological: MVA-BN-Filo Sponsors: Janssen Vaccines & Prevention B.V.; Bavarian Nordic GmbH Recruiting - verified November 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials